Abstract 3797
Background
To reveal candidate signaling pathways for targeted therapy in esophageal cancer (EC), and esophageal adenocarcinoma (EAC) in particular, we investigated key signal transduction pathways in material available in clinical routine, before and after neoadjuvant chemoradiation (nCRT), and for primary tumor and recurrent disease.
Methods
Paraffin-embedded material from three cohorts was used; (i) resectable EC; patients treated with an esophagectomy or receiving nCRT prior to resection, including cases with an available pre-nCRT biopsy of the primary tumor and corresponding resection; (ii) recurrent EC; patients of whom a resection and metachronous recurrence could be obtained. In addition, to explore the possibility to use patient-derived-xenografts (PDX) as a model to identify novel therapies, (iii) PDX of matched patient material was analyzed. Digitally annotated tumor areas ≥2 mm2 were transferred to a consecutive hematoxylin-stained slide and scraped for RNA extraction. Subsequently, a panel of qPCRs was performed, to infer signal transduction activity of the AR-, ER-, PI3K- (inverse of FOXO), HH-,TGF-β- and Wnt pathway.
Results
In pre-treatment EAC biopsies (i), high PI3K- and low TGF-β-pathway activity were correlated with poor pathological response. During treatment, a significant increase in PI3K- and decrease in TGF-β activity was observed in EAC poor nCRT responders compared to good responders (p = 0.003 and p = 0.042, respectively). Patients with a post-nCRT poor responder profile (high PI3K/ low TGF-β pathway activity) showed inferior disease free survival (median 17 vs. 97 months p = 0.055). Moreover, in nCRT treated patients, higher PI3K and lower TGF-β activities were seen in metachronous recurrences compared to resected tumors (ii) (p = 0.001 and p = 0.007, respectively). Pathway activity profiles were conserved between PDX and primary patient material (iii).
Conclusions
Loss of tumor-suppressive TGF-β and concurrent high PI3K pathway activity are associated with poor response to nCRT in EAC. This poor-responder profile is preserved in recurrences of nCRT pre-treated patients and PDX models, providing a valuable tool to experimentally test targeting candidate signal pathways such as PI3K.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Philips Research.
Funding
Philips Research.
Disclosure
L. Holtzer: Full / Part-time employment: Philips. M. Stoffels: Research grant / Funding (self), Full / Part-time employment: Philips. H. van Ooijen: Licensing / Royalties, Full / Part-time employment: Philips. A.G.C. van Brussel: Research grant / Funding (self), Licensing / Royalties, Full / Part-time employment: Philips. E.M.G. Aussems-Custers: Research grant / Funding (self), Licensing / Royalties, Full / Part-time employment: Philips. A. van de Stolpe: Licensing / Royalties, Full / Part-time employment: Philips. M.F. Bijlsma: Research grant / Funding (self): Celgene; Advisory / Consultancy: Servier. H.W.M. van Laarhoven: Advisory / Consultancy, Research grant / Funding (self): Celgene; Advisory / Consultancy, Research grant / Funding (self): BMS; Advisory / Consultancy, Research grant / Funding (self): Nordic; Advisory / Consultancy, Research grant / Funding (self): Lilly; Research grant / Funding (self): Merck Serono; Research grant / Funding (self): Bayer; Research grant / Funding (self): MSD; Research grant / Funding (self): Philips; Research grant / Funding (self): Roche. All other authors have declared no conflicts of interest.
Resources from the same session
3278 - Immune-Related Gene Expression Profiling after Neoadjuvant Chemotherapy (NACT) of Ovarian High-Grade Serous Carcinoma
Presenter: Luis Manso
Session: Poster Display session 2
Resources:
Abstract
4906 - Tumor-infiltrating lymphocytes (TILs) in patients with epithelial ovarian cancer undergoing neoadjuvant chemotherapy: A restrospective study
Presenter: Sara Giovannoni
Session: Poster Display session 2
Resources:
Abstract
3919 - Prognostic significance of elements of the adaptive immunity in the microenvironment of epithelial ovarian cancer.
Presenter: Periklis Foukas
Session: Poster Display session 2
Resources:
Abstract
5139 - Neutrophil-to-lymphocyte ratio predicts platinum sensitivity in epithelial ovarian cancer patients: a MITO24 retrospective study
Presenter: Alberto Farolfi
Session: Poster Display session 2
Resources:
Abstract
4212 - The prognostic impact of monocyte to lymphocyte ratio (MLR) in advanced epithelial ovarian cancer (EOC)
Presenter: Marc Cucurull Salamero
Session: Poster Display session 2
Resources:
Abstract
5123 - TP53 Hotspot mutations as immunoreactive neoantigens define a signature with differential survival outcomes in advanced ovarian cancer
Presenter: Marica Garziera
Session: Poster Display session 2
Resources:
Abstract
3795 - Use of bevacizumab (Bev) in real life for first-line (fl) treatment of ovarian cancer (OC)/ The GINECO ENCOURAGE cohort of 500 French patients
Presenter: Dominique Berton-Rigaud
Session: Poster Display session 2
Resources:
Abstract
2359 - Phase II study: Letrozole maintenance therapy after first line chemotherapy in patients with advanced serous and endometrioid ovarian cancer
Presenter: Alexandra Tyulyandina
Session: Poster Display session 2
Resources:
Abstract
3619 - Baseline IPI (Immune Prognostic Index) predicts survival in patients with advanced cervical cancer treated with immune checkpoint inhibitors (ICI).
Presenter: Felix Blanc-Durand
Session: Poster Display session 2
Resources:
Abstract
3474 - Preselecting tumor-infiltrating lymphocyte subsets to implement adoptive inmmunotherapy in ovarian cancer
Presenter: Diego Salas-Benito
Session: Poster Display session 2
Resources:
Abstract